drugset / Trial / NCT00932828

Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study

NCT00932828 ↗

Phase 2 Completed 37 enrolled University of North Carolina, Chapel Hill
NaSingle-groupOpen-labelTreatment

Summary

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

Timeline

Start
2009-06-22
Primary completion
2017-02-01
Completion
2017-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Defatted peanut Unknown 300 mg Oral
Subject Defatted peanut Unknown 3000 mg Oral

Indications